EGFR and head and neck squamous cell carcinoma: Until recently, first-line systemic treatment for recurrent or metastatic HNSCC patients has been based on the EXTREME regimen, a platinum-based chemotherapy (cisplatin or carboplatin and fluorouracil) with cetuximab, an IgG1 chimeric monoclonal antibody to epidermal growth factor receptor (EGFR) [6].